Targeted therapy for leptomeningeal metastases in non-small cell lung cancer – Changing treatment paradigms

• DOI: 10.21147/j.issn.1000-9604.2017.06.08
• Publication Date: 2018-01-10T00:07:11Z
• Authors: Binay Kumar Shah; ; Isaac Pak; Nibash Budhathoki; Kayla Buker
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Leptomeningeal metastasis is an uncommon but serious complication in patients with advanced cancers. Leptomeningeal metastasis is diagnosed in approximately 5% of the patients, most commonly among patients with cancers of breast and lung, melanoma, and gastrointestinal malignancies. Treatment goal is to improve survival and quality of the patients. Use of targeted therapies and immunotherapy has led to improved survival of patients with non-small cell lung cancer (NSCLC). In this article, we review emerging data on use of mutation-specific agents and immunotherapy in the treatment of leptomeningeal metastasis among patients with NSCLC.